Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
6 hedge funds and large institutions have $80.2K invested in Achilles Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 16 closing their positions.
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
71% less funds holding
Funds holding: 21 → 6 (-15)
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 16
100% less capital invested
Capital invested by funds: $27.7M → $80.2K (-$27.6M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$15.7K |
| 2 |
GI
GAMMA Investing
Foster City,
California
|
+$1.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SP
Syncona Portfolio
St Peter Port,
Guernsey
|
-$12.6M |
| 2 |
FIS
FCPM III Services
Naarden,
Netherlands
|
-$2.75M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$1.83M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$1.71M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.64M |
ACHL Hedge Fund Activity: Q1 2025 in Review
6 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q1 2025, worth a combined $80.2K — down 100% from $27.7M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ACHL and 1 opened new positions — a net loss of 15 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was XTX Topco, adding an estimated $15.7K. The largest seller was Syncona Portfolio, exiting entirely with an estimated $12.6M sold.
- 6 institutional investors held Achilles Therapeutics (ACHL) as of Q1 2025, down from 21 in Q4 2024.
- Funds reported $80.2K of Achilles Therapeutics stock for Q1 2025, down 100% quarter-over-quarter.
- 1 fund opened new Achilles Therapeutics positions in Q1 2025 and 16 closed out, a net change of -15 holders.
- The largest Achilles Therapeutics buyer in Q1 2025 was XTX Topco, an estimated $15.7K added.
- The largest Achilles Therapeutics seller in Q1 2025 was Syncona Portfolio, an estimated $12.6M sold.
Based on aggregated 13F filings for Q1 2025.